EMA taking second hard look at Ariad's Iclusig

The European Medicines Agency (EMA) has decided to look again at the clotting risks of Ariad Pharmaceuticals' ($ARIA) troubled cancer drug Iclusig. The FDA recently had the company pull the drug. Shares of the company fell 10%. Story | More